Fractyl Health (GUTS) Set to Post Earnings on Wednesday

Fractyl Health (NASDAQ:GUTS) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Fractyl Health to announce earnings of ($1.59) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. On average, analysts expect Fractyl Health to post ($5.88) EPS for the current fiscal year and ($4.87) EPS for the next fiscal year.

Fractyl Health Stock Up 4.7%

NASDAQ:GUTS traded up $0.04 during trading hours on Wednesday, reaching $0.94. The company’s stock had a trading volume of 63,620 shares, compared to its average volume of 340,893. The stock has a 50 day moving average price of $5.13 and a two-hundred day moving average price of $7.80. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The company has a market capitalization of $12.46 million, a P/E ratio of -0.09 and a beta of 2.91. Fractyl Health has a 12 month low of $0.82 and a 12 month high of $29.34.

Wall Street Analysts Forecast Growth

GUTS has been the topic of a number of research reports. Craig Hallum set a $5.00 target price on shares of Fractyl Health in a research report on Monday, October 19th. Morgan Stanley decreased their target price on shares of Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a research note on Monday, October 19th. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings cut shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $50.25.

Fractyl Health Company Profile

Fractyl Health, Inc is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines.

Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).